CASI CASI Pharmaceuticals
- 2.6500
- +0.0270+1.03%
CASI Pharmaceuticals News
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong I
CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute With Juventas Cell Therapy Ltd Prohibiting Juventas From Commercializing CNCT19
On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company ("CASI" or the "Company") announced that, with respect to the Company's previously announced dispute with Juventas
Recap: CASI Pharmaceuticals Q4 Earnings
CASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCASI Pharmaceuticals misse
CASI Pharmaceuticals GAAP EPS of -$2.02, Revenue of $33.88M
CASI Pharmaceuticals 4Q Rev $6.9M >CASI
CASI Pharmaceuticals 4Q Rev $6.9M >CASI
Hy-Tek Intralogistics and CASI Announce Partnership
COLUMBUS, OH., March 19, 2024 /PRNewswire/ -- Hy-Tek Intralogistics, a premier integrator of full-service automation technology for the supply chain, has partnered with CASI, a leading provider of tu
AstraZeneca-Fusion Deal Reignites Radiopharma Space
12 Health Care Stocks Moving In Friday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of their outstanding shares is at $40.4 million. Ainos (NASDAQ:AIMD) sto
Aptevo Therapeutics, Immuron, CASI Pharmaceuticals Among Healthcare Movers
BYSI, PHUN and DTSS Among Pre-market Losers
Top Midday Gainers
Datasea (DTSS) said Tuesday it expects revenue of about $86 million during the fiscal year ended June 30, compared with $7 million a year ago. Shares surged 74% as intraday trading volume shot up to m
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin's Lymphoma (iNHL) in the ongoing development program in China.
CASI Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 13.1%
CASI Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 13.1%
CASI Stock Rises on Positive Interim Data From Early Stage Trial for Its NHL Treatment in China
CASI Pharmaceuticals CASI Phase 1 Initial Data; Apogee APGE Phase 1 Data & Earnings
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersSunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 55.9% to $0.07 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.8 million. CASI Pharmaceuticals
CASI Pharma Shares Soar After Positive Preliminary Trial Data for Cancer Immunotherapy
By Robb M. Stewart CASI Pharmaceuticals' shares rallied ahead of the bell Tuesday after the biopharmaceutical company disclosed preliminary encouraging efficacy data for an early-stage trial of a ful
Analysis
Price Target
No Data
